Rachel E. Davis
University of Notre Dame(US)UCB Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
Heat shock proteins research, Computational Drug Discovery Methods, ATP Synthase and ATPases Research, DNA Repair Mechanisms, HER2/EGFR in Cancer Research
Most-Cited Works
- → A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors(2021)326 cited
- → 6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity(2001)272 cited
- → Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)(2002)263 cited
- → Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer(2019)124 cited
- → Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF(2021)84 cited
- → Selective Inhibition of the Hsp90α Isoform(2021)72 cited
- → Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells(2017)33 cited
- → Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain(2018)19 cited
- → NaViA: a program for the visual analysis of complex mass spectra(2021)18 cited
- → Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors(2020)17 cited